CD123-Targeted Therapy to Achieve Negative Measurable Residual Disease in Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm Prior to Transplantation.

IF 2.3 3区医学 Q2 HEMATOLOGY

Pediatric Blood & Cancer Pub Date : 2025-09-12 DOI:10.1002/pbc.32034

Flavia Gava, Luiz Fernando Bazzo Catto, Marilia Bazzo Catto, Ana Luiza Morais, Maristella Bergamo Francisco Dos Reis, Thiago Eleuterio Gonçalves, Luiz Guilherme Darrigo, Carlos Alberto Scrideli, Elvis Terci Valera

引用次数: 0

查看原文本刊更多论文

cd123靶向治疗在移植前实现儿童母浆细胞样树突状细胞肿瘤的阴性可测量残留病

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Blood & Cancer 医学-小儿科

CiteScore

4.90

自引率

9.40%

发文量

546

审稿时长

1.5 months

期刊介绍： Pediatric Blood & Cancer publishes the highest quality manuscripts describing basic and clinical investigations of blood disorders and malignant diseases of childhood including diagnosis, treatment, epidemiology, etiology, biology, and molecular and clinical genetics of these diseases as they affect children, adolescents, and young adults. Pediatric Blood & Cancer will also include studies on such treatment options as hematopoietic stem cell transplantation, immunology, and gene therapy.